Your right nothing to see here.

Excellent. So we have real world confirmation Rett Syndrome News seems to me. Thanks for posting.

Business update on next leg up. Deals take time.

I want the stock price to move up from here. Some want the stock price to move down so they can re-enter. Will 2 cents happen likely not within the next few weeks as Leo said news shortly..

Share price found it's footing. Solid 6% move.

Antibiotics are the bees knees if given early enough. B is being further studied for a reason this we know.

Got some nice traction off .038. Somebody's buying.

Somebody getting in bigly. Let's go.

It was a worthy "share holder" news letter. The broader public lol

They will be too upset.

Collaborative work with NIH and other researchers on Brilacidin’s broad-spectrum antiviral properties is ongoing and generating promising data, with future updates planned.

You are correct is my belief also. My opinion is one hallmark of a scam is they never produce an IND for trial. IPIX has run multiple FDA approved trials.

Share holder update. What ever they're incubating it's not quite finished.

There was a lot in that Dec 7 pr, it's now Jan 24. Should get an update on all the government testing. Really like to see a term sheet.

I just hope we get some solid news next cycle. Fluff is not going to cut it.

I agree somethings cooking. Looking forward to the next update.

Leo's likely working to provide solid a update, for that I don't mind this quiet period. I don't want some fluff pr stating they are laser focused on multiple fronts or some such nonsense.

Somebody purposely cuts the ask. Pay the ask and you get the shares below the ask.

This March 11, 2020 Defensins as Vaccines Brilacidin

Academic Literature Supporting Brilacidin’s Vaccine Potential Against COVID-19

Vaccines containing defensins as adjuvants have been shown, both in vivo and in vitro, to activate the primary innate antiviral immune response and mediate other immunomodulatory activities against a number of viruses, including coronaviruses, such as MERS-CoV.

Defensins and their mimetics, like Brilacidin, thus represent a promising therapeutic avenue as vaccines to target COVID-19, the deadly respiratory disease caused by the novel coronavirus SARS-CoV-2, which has emerged as a worldwide pandemic.

Supported by scientific research, Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials for other clinical indications, providing an established safety and efficacy profile, thereby potentially enabling it to rapidly help address the emerging worldwide coronavirus crisis, developed both as an intravenous medicine and as a vaccine.

“In addition to their antibacterial and antiviral activity, defensins are one of the strongest central and peripheral defenders against pathogen infection, particularly in linking innate and adaptive immunity against pathogen infection…

I hope they go back to this research.

Thanks. Hoping to make a bit. Everything depends on what Leo has to say.

Today I threw caution to the wind figuring Leo has a rescue plan. No safe place in these trying times. I plan to go back into I-Bonds and TIPS this spring.

I bought more today. Leo's awfully quiet in the face of things.

What he is doing is all in the last press release. There's a lot in there.

He said 2022 could be transformational.. Hopefully we transform into a well funded bio.

“The Company is moving ahead with a strategic focus. Efforts are underway to advance Brilacidin’s clinical development on multiple fronts, as well as to explore potential new pipeline additions that could be transformational for our company in 2022.”

William F. Degrado, Phd

Scientific Advisor, Drug Discovery and Clinical Development

He's still listed on the IPIX board. I would bet it was Dr Degrado that got B into the university viral testing labs. Hopefully we hear news on that testing soon.

From Oct25- "The Company is also pleased to report Brilacidin has been shipped to two academic laboratories for planned in vitro testing of Brilacidin in over 20 acutely infectious viruses, including Ebola, Marburg, Nipah, West Nile and Zika, through a collaboration with U.S. government scientists. The goal of this testing is to further inform the spectrum of Brilacidin’s antiviral properties".

Per update ebola testing did happen so has somebody heard something.

Leo's been quiet since the last press release where he said they were in discussions. Wait and see.

It's been a while I figure next news cycle will have some meat on the bone. I added today and with 2.4m shares traded I'm definitely not alone here. Leo make something happen and getter done.

An effective Brilacidin pill for UC would likely be safer and much less expensive to dose then an IV given monoclonal antibody. But we need a finished pill and a trial to find that out. Ok Leo.

Oh yeah. Good news would put some gas in the share price.

“Among critically-ill patients who received Brilacidin under compassionate use in an open label manner, we were told noticeable improvements were seen in key inflammatory biomarkers shortly after receiving Brilacidin treatment.

Should hear more on this soon. A win here should give further B studies weight.

We need to see a term sheet or grant funding sooner rather then later to really move assets forward. Leo say's he's in discussions to enter in new licensing agreements which sounds like direct talks as there was no mention of Locust Walk.

IPIX management needs a team to help broker as well as lawyers helping work any licensing agreements. Maybe there is a knowledgeable team but we just don't know. B has shown promise to be a multi-billion dollar compound so why not take some cash on hand to add real professionals to build up the company from where we are. Go 2022.

You know you will never leave. Stock runs and greed kicks in maybe it's madness. Wishing all a happy 2022.

Prayers to our nation for healing, mercy and forgiveness.

Leo reported being in discussions to acquire rights to new pipeline as well as to enter into new licensing agreements. We could start seeing results coming in regarding the in vitro studies of the 20+ acutely infectious virus. This is what has my interest. Go 2022

Let's see where this leads in 2022. "Innovation management is engaged in discussions potentially to acquire rights to new pipeline assets, as well as to enter into new licensing agreements".

Hopefully we get more on this soon.

It is of no matter. What matters is what Leo does next.

Elsewhere, Innovation management is engaged in discussions potentially to acquire rights to new pipeline assets, as well as to enter into new licensing agreements.

Ehrlich added, "The Company is moving ahead with a strategic focus. Efforts are underway to advance Brilacidin's clinical development on multiple fronts, as well as to explore potential new pipeline additions that could be transformational for our company in 2022."

Buys can be marked as sells and vice versa due to algorithms. Not sure what your seeing but selling at and below the bid by mm's does happen causing price to decline.

Tells me it will be revealed when they finish. Merry Christmas!

Your describing a broad spectrum anti-viral..Go B.

Yep but it will be tough for the lock down know it all's to give up the cash cow.

And you thought he did..funny.